Hospital Santa Creu i Sant Pau
Barcelona, 08025, Spain
NCT Number: NCT00863577
The primary pharmacokinetic analysis will be the correlation of the AUC amidolytic anti-Xa activity
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Barcelona, 08025, Spain
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bemiparin tablets and bemiparin tablets into hard gelatine capsules
Time frame: pre-medication, +1 h , +2 h, +3h, +4 h , +5h, +6 h, +8 h, +10h, +12h, +18 h, +24 h,+25h, +26h, +27h, +28h, +29h, +30h, +32h, +34h, +36h, +42h, +48 h, +60 h and +72 h
Rovi Pharmaceuticals Laboratories
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07724015
Healthy
Jaén, Spain
View Trial DetailsNCT07404254
Beverage Intake, Caffeine
San Francisco, California, United States
View Trial DetailsNCT07466667
Healthy
Ahmedabad, Gujarat, India
View Trial DetailsNCT07357818
Beverage Intake, Caffeine
San Francisco, California, United States
View Trial Details